Clinical Global Impressions ‐ Improvement of condition (CGI‐I) Rating of 1 = very much improved to 7 = very much worse · adults with seasonal affective disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life (SF‐20 & Q‐LES‐Q) Eight weeks · adults with seasonal affective disorder
1 finding from 1 review
Disability (primary analysis) · people with stroke recovery
1 finding from 1 review
Independent on modified Rankin score (mRS 0 to 2) (primary analysis) · people with stroke recovery
Fluoxetine showed no clear difference in independent on modified Rankin score (mRS 0 to 2) (primary analysis) compared with control at end of treatment, (high certainty).
1 finding from 1 review
Neurological deficit score · people with stroke recovery
1 finding from 1 review
no estimate extracted
30 participants
Low
Depressive symptoms · people with stroke recovery
1 finding from 1 review
Death · people with stroke recovery
Fluoxetine showed no clear difference in death compared with control at end of treatment, (moderate certainty).
1 finding from 1 review
Seizures · people with stroke recovery
Fluoxetine showed no clear difference in number of seizures compared with control at end of treatment, (moderate certainty).
1 finding from 1 review
Fracture · people with stroke recovery
Fluoxetine leads to higher bone fractures compared with control at end of treatment, (high certainty).
1 finding from 1 review
Weight loss (change in kg weight) · overweight or obese adults
1 finding from 1 review
Health‐related quality of life · overweight or obese adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Any adverse event (N) · overweight or obese adults
Summary of findings: fluoxetine showed no clear difference in any adverse event (N) compared with placebo (low certainty).
1 finding from 1 review
Anthropometric measurements other than weight loss in kg (BMI reduction measured inkg/m²) · overweight or obese adults
1 finding from 1 review
Morbidity: depression (N) · overweight or obese adults
It is very uncertain whether summary of findings: fluoxetine changes morbidity: depression (N) compared with placebo (very low certainty).
1 finding from 1 review
All‐cause mortality · overweight or obese adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Socioeconomic effects · overweight or obese adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life ‐ not measured · treatment‐resistant depression in adults
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Depressive symptoms · treatment‐resistant depression in adults
1 finding from 1 review
Leaving the study early · treatment‐resistant depression in adults
Augmentation of current antidepressant (fluoxetine 20 mg/d) with… showed no clear difference in dropouts compared with augmentation of current antidepressant (fluoxetine 20 mg/d) with… (low certainty).
1 finding from 1 review
Proportions of participants responding to treatment ≥ 50% reduction in depression score from baseline to end of treatment. A larger RR indicates greater response to treatment in the SAMe group · treatment‐resistant depression in adults
Augmentation of current antidepressant (fluoxetine 20 mg/d) with… may leads to higher response (≥ 50% reduction in HAM‐D score) compared with augmentation of current antidepressant (fluoxetine 20 mg/d) with… (low certainty).
1 finding from 1 review